Investigating how radiation therapy can improve treatment for limited metastatic prostate cancer.
Official title: Radiation Oncology-Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center
Funded at University of Maryland Baltimore · NIH-10910075 · Data updated 2026-11-12
This study is looking at how radiation therapy can help men with prostate cancer that has spread to a few places in the body, aiming to see if it can stop the cancer from getting worse and improve treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 4, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,428,096 |
| NIH project number | 5U54CA273956-03 |
| Project ID | NIH-10910075 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with oligometastatic prostate cancer who have limited metastases.
✕Less likely to help
Patients with advanced metastatic prostate cancer that is not oligometastatic may not benefit from this research.
What this research studies
This research focuses on understanding the complex process of metastasis in prostate cancer, particularly in cases where the cancer has spread but remains limited in number and location, known as oligometastasis. The study aims to explore how radiation therapy can be used to consolidate tumor deposits and potentially prevent further progression of the disease. By collaborating with experts from multiple prestigious institutions, the research employs advanced clinical trials and computational methods to analyze the effects of radiation on metastatic cancer. Patients may benefit from new treatment strategies that could enhance their management and outcomes.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with oligometastatic prostate cancer, potentially increasing survival rates and quality of life.
How similar studies have gone: Previous studies have shown promising results in using radiation therapy for oligometastatic prostate cancer, indicating that this approach may be effective.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Tran, Phuoc T. — University of Maryland Baltimore
- Study coordinator: Tran, Phuoc T.
Related research
Other NIH-funded projects on the same topics.
-
ROBIN OligoMET Center: Radiation and Biology Insights for Prostate Cancer Metastasis
A nationwide collaboration is testing how targeted radiation can alter the spread of prostate cancer that has few metastases, with the goal of improving control of the disease.
-
Understanding Radiation for Prostate Cancer with Limited Spread
This research brings together experts to learn how radiation therapy can help patients with prostate cancer that has spread to only a few spots.
-
Adding targeted stereotactic body radiation therapy to standard systemic treatment for people with oligometastatic urothelial (bladder) carcinoma.
This study will test whether adding stereotactic body radiation therapy (SBRT) to usual systemic treatment helps people with urothelial (bladder) cancer who have up to three extracranial metastases.
-
Stereotactic body radiotherapy for extracranial oligometastatic breast cancer
This project sees if stereotactic body radiotherapy (SBRT) helps control cancer and extend survival in adults with extracranial oligometastatic breast cancer.
-
Stereotactic body radiotherapy (SABR) for limited metastases
This program tries stereotactic body radiotherapy (SABR) in people with up to five oligometastatic or oligoprogressive cancer lesions to see if it controls disease better, affects symptoms and side effects, and changes ctDNA in the blood.
-
Immediate simulation-free SBRT for people with up to five metastatic tumors
This tests whether giving stereotactic body radiation therapy (SBRT) right away without a separate CT simulation helps people with up to five metastatic cancer spots get treatment faster.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.